The role of protamine amount in the transfection performance of cationic SLN designed as a gene nanocarrier

Vighi, Eleonora; Montanari, Monica; Ruozi, Barbara; Iannuccelli, Valentina; Leo, Eliana Grazia

doi:10.3109/10717544.2011.621989

Cited by 17 publications

(28 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cationic property the NLCs is due to the DDAB as surfactant used during preparation. Positive charge of the nanocarriers could exploit the negative charged cells due to the electrostatic interactions, thus increase the cellular uptake (Xu et al, 2012;Vighi et al, 2012). The EE of DOX and VCR loaded in DOX/VCR NLCs and single drug NLCs were above 80%.…”

Section: Nlcs Characterizationmentioning

confidence: 88%

Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo

Dong¹,

Wang²,

et al. 2015

Drug Delivery

View full text Add to dashboard Cite

Purpose: Lymph cancers are heterogeneous malignancies of the hematopoietic and lymphoid tissues. Doxorubicin (DOX) and vincristine (VCR) are commonly used anti-cancer chemotherapeutic drugs, but their clinical uses are associated with dose-limiting systemic toxicity. Methods: In the present study, DOX and VCR were encapsulated into nanostructured lipid carriers (NLCs) and used them to treat B-cell lymphoma cells through the targeted delivery of DOX and VCR to lymph cancer animal model. Results: DOX and VCR encapsulated NLCs (DOX/VCR NLCs) demonstrated controlled drug release under physiological conditions. In addition, DOX/VCR NLCs exhibited the highest cytotoxicity and synergistic effect of two drugs in B-cell lymphoma cells and the best antitumor effect in vivo. Conclusion: DOX/VCR NLCs were proved to be more efficacious than the equivalent dose of free DOX and single drug (DOX or VCR) formulation in vitro and in vivo, and significantly reduced the drug-associated systemic toxicity.

show abstract

Section: Nlcs Characterizationmentioning

confidence: 88%

Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo

Dong¹,

Wang²,

et al. 2015

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Can undergo steam sterilization, lyophilization, Cytotoxicity due to cationic surfactants, emulsifiers and preservatives in the formulation (Vighi et al, 2012;Ma et al, 2015) Cationic liposomes Biodegradability, biocompatibility, low immunogenicity, simplicity, reproducibility Serikawa et al, 2008;Dizaj et al, 2014) …”

Section: Disclosure Statementmentioning

confidence: 99%

Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides

2017

View full text Add to dashboard Cite

As a prototypical pro-inflammatory transcription factor, constitutive activation of NF-κB signaling pathway has been reported in several chronic inflammatory disorders including inflammatory bowel disease, cystic fibrosis, rheumatoid arthritis and cancer. Application of decoy oligodeoxynucleotides (ODNs) against NF-κB, as an effective molecular therapy approach, has brought about several promising outcomes in treatment of chronic inflammatory disorders. However, systematic administration of these genetic constructs is mostly hampered due to their instability, rapid degradation by nucleases and poor cellular uptake. Both chemical modification and application of delivery systems have shown to effectively overcome some of these limitations. Among different administered delivery systems, nanomaterials have gained much attention for delivering NF-κB decoy ODNs owing to their high loading capacity, targeted delivery and ease of synthesis. In this review, we highlight some of the most recently developed nanomaterial-based delivery systems for overcoming limitations associated with clinical application of these genetic constructs.

show abstract

“…However, non-viral nano-vectors usually show low transfection efficiencies . Innovative cationic lipid nanocarriers, such as liposomes (Brgles et al, 2012), emulsions (Bozelli et al, 2012), and solid lipid nanoparticles (Choi et al, 2008;Tabatt et al, 2004a;Vighi et al, 2012), have been therefore tested in the transfection of proteins and nucleic acids.…”

Section: Introductionmentioning

confidence: 99%

Development and characterization of a cationic lipid nanocarrier as non-viral vector for gene therapy

Severino

Szymanski

Favaro

et al. 2015

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

The role of protamine amount in the transfection performance of cationic SLN designed as a gene nanocarrier

Cited by 17 publications

References 30 publications

Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo

Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo

Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides

Development and characterization of a cationic lipid nanocarrier as non-viral vector for gene therapy

Contact Info

Product

Resources

About